Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001437749-22-008801
Filing Date
2022-04-13
Accepted
2022-04-13 09:22:32
Documents
13
Period of Report
2022-03-25
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K/A cbli20220412_8ka.htm   iXBRL 8-K/A 32922
  Complete submission text file 0001437749-22-008801.txt   174744

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA stab-20220325.xsd EX-101.SCH 3602
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE stab-20220325_def.xml EX-101.DEF 12292
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE stab-20220325_lab.xml EX-101.LAB 16482
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stab-20220325_pre.xml EX-101.PRE 12558
7 EXTRACTED XBRL INSTANCE DOCUMENT cbli20220412_8ka_htm.xml XML 2815
Mailing Address 2537 RESEARCH BOULEVARD, SUITE 201 FORT COLLINS CO 80526
Business Address 2537 RESEARCH BOULEVARD, SUITE 201 FORT COLLINS CO 80526 (888) 613-8802
Statera Biopharma, Inc. (Filer) CIK: 0001318641 (see all company filings)

EIN.: 200077155 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-32954 | Film No.: 22823821
SIC: 2834 Pharmaceutical Preparations